Tofogliflozin hydrate

• CAT Number: I000741
• CAS Number: 1201913-82-7
• Molecular Formula: C22H28O7
• Molecular Weight: 404.45
• Purity: ≥95%
• Target: NF-κB
• Solubility: 10 mM in DMSO
• Storage: 3 years -20C powder
• IC50: 2.9/14.9/6.4 nM(human/rat/mouse SGLT2) [1]
• IUPAC Name: (3S,3'R,4'S,5'S,6'R)-5-[(4-ethylphenyl)methyl]-6'-(hydroxymethyl)spiro[1H-2-benzofuran-3,2'-oxane]-3',4',5'-triol;hydrate
• InChI: InChI=1S/C22H26O6.H2O/c1-2-13-3-5-14(6-4-13)9-15-7-8-16-12-27-22(17(16)10-15)21(26)20(25)19(24)18(11-23)28-22;/h3-8,10,18-21,23-26H,2,9,11-12H2,1H3;1H2/t18-,19-,20+,21-,22+;/m1./s1
• InChIKey: ZXOCGDDVNPDRIW-NHFZGCSJSA-N
• SMILES: CCC1=CC=C(C=C1)CC2=CC3=C(COC34C(C(C(C(O4)CO)O)O)O)C=C2.O

Tofogliflozin Hydrate（Cat No.:I000741）is an SGLT2 inhibitor used to manage type 2 diabetes mellitus. By blocking the sodium-glucose co-transporter 2 in the kidneys, it reduces glucose reabsorption, promoting the excretion of excess glucose through urine. This mechanism helps lower blood sugar levels and provides additional benefits such as weight loss and improved cardiovascular health. Tofogliflozin Hydrate is effective in controlling hyperglycemia, making it a valuable option in diabetes treatment regimens, particularly for patients needing improved glycemic control and overall metabolic health management.